American Diabetes Association
Online_Supplemental_Materials.pdf (300.98 kB)

Evaluation of Evidence for Pathogenicity Demonstrates that BLK, KLF11 and PAX4 Should not be Included in Diagnostic Testing for MODY

Download (300.98 kB)
posted on 2022-02-02, 19:43 authored by Thomas W Laver, Matthew N Wakeling, Olivia Knox, Kevin Colclough, Caroline F Wright, Sian Ellard, Andrew T Hattersley, Michael N Weedon, Kashyap A Patel
Maturity Onset Diabetes of the Young (MODY) is an autosomal dominant form of monogenic diabetes, reported to be caused by variants in 16 genes. Concern has been raised about whether variants in BLK (MODY11), KLF11 (MODY7) and PAX4 (MODY9) cause MODY. We examined variant-level genetic evidence (co-segregation with diabetes and frequency in population) for published putative pathogenic variants in these genes and used burden testing to test gene-level evidence in a MODY cohort (n=1227) compared to population control (UK Biobank, n=185,898). For comparison we analysed well-established causes of MODY, HNF1A and HNF4A. The published variants in BLK, KLF11 and PAX4 showed poor co-segregation with diabetes (combined LOD scores ≤1.2), compared to HNF1A and HNF4A (LOD scores >9), and are all too common to cause MODY (minor allele frequency >4.95x10-5). Ultra-rare missense and protein-truncating variants (PTVs) were not enriched in a MODY cohort compared to the UK Biobank (PTVs P>0.05, missense P>0.1 for all three genes) while HNF1A and HNF4A were enriched (P<10-6). Sensitivity analyses using different population cohorts supported our results. Variant and gene-level genetic evidence does not support BLK, KLF11 or PAX4 as causes of MODY. They should not be included in MODY diagnostic genetic testing.


This research has been conducted using the UK Biobank Resource under Application Number 49847. The current work was funded by Diabetes UK (19/0005994) and the MRC (grant no MR/T00200X/1).